Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
|
|
- Merry Dixon
- 6 years ago
- Views:
Transcription
1 formulry Mngement Formulry Mngement of the Protese Inhiitors Boeprevir nd Telprevir for Chroni Heptitis C Virus Alexndr Tungol, PhrmD; Kellie Rdemher, PhrmD; nd Jeremy A. Shfer, PhrmD, MBA ABSTRACT Bkground: Heptitis C virus (HCV) is the most ommon hroni loodorne illness in the United Sttes. The inidene of ute heptitis C in the United Sttes peked ner 50,000 ses in the lte 1980s ut hs stilized sine 2003 to less thn 5,000 ses nnully. The omintion of pegylted interferon (peginterferon) nd rivirin hs een the stndrd reommended tretment for HCV. Protese inhiitors telprevir nd oeprevir were pproved y the FDA in My 2011 for the tretment of heptitis C genotype 1 in omintion with peginterferon nd rivirin. Ojetive: To review the phse 3 trils for telprevir nd oeprevir nd provide mnged re onsidertions. Methods: A MEDLINE review ws performed for rtiles pulished nd ville through Septemer 15, 2011, using keywords oeprevir or telprevir with n emphsis on phse 3 trils. The literture serh ws limited to rtiles in English, linil trils, rndomized ontrolled trils, nd reserh onduted in humns. Additionl informtion ws otined from the FDA wesite. Results: Three phse 3 trils re ville for telprevir, whih provided dt tht were the sis for FDA pprovl. Boeprevir demonstrted effiy nd sfety in 2 pivotl phse 3 trils. Both gents demonstrted sttistilly signifintly higher rtes of virologi response ompred with the stndrd of re involving peginterferons nd rivirin. Telprevir nd oeprevir lso demonstrted effiy in the tretment of ptients who hd previously filed dul therpy for heptitis C. Sfety onerns for oth gents inlude nemi, drug intertions, skin rshes, nd gstrointestinl dverse events. Conlusions: Deision mkers hve mny ftors to onsider in developing strtegy round heptitis C. Inresed drug osts, ptient mngement, dherene, omprtive sfety nd effiy, nd pproprite utiliztion mngement ontrols re importnt issues. Pyers my onsider developing linil progrms to enourge dherene nd pproprite use nd leverge n pproprite hnnel to ensure ost-effetive therpy. J Mng Cre Phrm. 2011;17(9): Copyright 2011, Ademy of Mnged Cre Phrmy. All rights reserved. Wht is lredy known out this sujet Historilly, the stndrd of re for the tretment of heptitis C hs een pegylted interferon (peginterferon) nd rivirin. The protese inhiitors telprevir nd oeprevir were pproved y the FDA in My 2011 for the tretment of heptitis C genotype 1 in omintion with peginterferon nd rivirin. Neither protese inhiitor my e used s monotherpy for heptitis C. Wht this review dds The urrent Amerin Assoition for the Study of Liver Diseses (AASLD) Prtie Guidelines (2011) reommend triple therpy with protese inhiitor, peginterferon, nd rivirin s the stndrd tretment for heptitis C. Both telprevir nd oeprevir hve een studied in tretmentnïve nd previous prtil responders, ut only telprevir hs een studied in prior null responders. Mnged re onsidertions of heptitis C pertinent to deision mkers inlude inresed totl drug tretment osts nd potentil inrese in utiliztion, ptient mngement nd dherene, omprtive sfety nd effiy, nd pproprite utiliztion mngement ontrols. The 12-week regimen of telprevir therpy hs wholesle quisition ost (WAC) in 2011 of $49,200 (dded to $17,175 WAC for 24 weeks of peginterferon plus rivirin [PR] or $34,349 for 48 weeks of PR). The oeprevir WAC in 2011 is $26,410 for the 24-week regimen (dded to $20,037 WAC for PR for 28 weeks, $25,762 for 36 weeks, or $34,349 for 48 weeks). Rtes of nemi were 36% in the telprevir-treted ptents versus 17% for ptients treted only with peginterferon nd rivirin. Anemi ourred in 45%-50% of oeprevir-treted ptients versus 20%-30% of ptients treted only with peginterferon nd rivirin; erythropoiesis-stimulting gents were used to mnge nemi in 43% of oeprevir-treted ptients versus 24% of ptients treted only with peginterferon nd rivirin. Heptitis C virus (HCV) is the most ommon hroni loodorne illness in the United Sttes. Approximtely 3.9 million people in the United Sttes hve hroni infetion. 1 HCV is leding use of liver trnsplnt nd liver ner in the United Sttes nd worldwide. 2,3 The inidene of ute heptitis C in the United Sttes peked ner 50,000 ses in the lte 1980s ut hs stilized sine 2003 to less thn 5,000 ses nnully. 4 The progressive deline my e result of inresed edution nd puli wreness of trnsmissile risk ftors. 4 Wong et l. (2000) estimted tht diret medil expenditures for HCV would grow to $10.7 illion over the period despite stle disese rte. 5 HCV is trnsmitted y exposure to infeted lood or lood produts with injetle drug use eing the leding use. 6 HCV hs t lest 6 genotypes nd 50 different sutypes (i.e., HCV sutype 1, 1, et.), with genotype 1 eing the most Vol. 17, No. 9 Novemer/Deemer 2011 JMCP Journl of Mnged Cre Phrmy 685
2 TABLE 1 FDA-Approved Inditions, Dose, Administrtion, nd Drug Cost for Telprevir nd Boeprevir for HCV Infetion Drug Dose nd Administrtion, FDA-Approved Indition Peginterferon + Rivirin Drug Cost Telprevir (Inivek) 375 mg tlets Boeprevir (Vitrelis) 200 mg psules 2 tlets (750 mg) 3 times dily (7-9 hours prt) for 12 weeks (ll ptients) INCIVEK must e dministered with oth peginterferon lf nd rivirin for ll ptients for 12 weeks, followed y response-guided regimen of either 12 or 36 dditionl weeks of peginterferon lf nd rivirin depending on virl response nd prior response sttus. Initite therpy with peginterferon lf nd rivirin for 4 weeks prior to strting oeprevir (led-in phse) At tretment week 4, dd oeprevir 800 mg (four 200 mg psules) orlly 3 times dily (every 7-9 hours) with food ( mel or light snk) VICTRELIS must e dministered in omintion with peginterferon lf nd rivirin. 24 weeks for undetetle HCV RNA t weeks 8 nd 24 for tretment-nïve ptients 32 weeks for undetetle HCV RNA t weeks 8 nd 24 for prior-relpse nd prtil-responder ptients 32 weeks for detetle (>9.3 IU per ml) HCV RNA t week 8 nd undetetle t week 24 for tretment-nïve, prior-relpse nd prtil-responder ptients Ptients with irrhosis: 4 weeks peginterferon lf nd rivirin (led-in phse) followed y 44 weeks oeprevir 800 mg (four 200 mg psules) 3 times dily (every 7-9 hours) in omintion with peginterferon lf nd rivirin In omintion with peginterferon lf nd rivirin, for the tretment of genotype 1 hroni heptitis C (CHC) in dult ptients with ompensted liver disese, inluding irrhosis, who re tretment-nïve or who hve een previously treted with interferon-sed tretment, inluding prior null responders, prtil responders, nd relpsers. INCIVEK must not e used s monotherpy nd must only e used in omintion with peginterferon lf nd rivirin. A high proportion of previous null responders (prtiulrly those with irrhosis) did not hieve SVR nd hd telprevir resistne-ssoited sustitutions emerge on tretment with INCIVEK. INCIVEK effiy hs not een estlished for ptients who hve previously filed therpy with tretment regimen tht inludes INCIVEK or other HCV NS3/4A protese inhiitors. For the tretment of hroni heptitis C (CHC) genotype 1 infetion, in omintion with peginterferon lf nd rivirin, in dult ptients ( 18 yers of ge) with ompensted liver disese, inluding irrhosis, who re previously untreted or who hve filed previous interferon nd rivirin therpy. 24 weeks for undetetle HCV RNA t weeks 4 nd 12 for tretmentnïve nd prior-relpse ptients 48 weeks for detetle (1,000 IU per ml or less) HCV RNA t weeks 4 nd 12 for tretmentnïve nd prior-relpse ptients 48 weeks for undetetle HCV RNA t weeks 4 nd 12 for tretmentnïve ptients with irrhosis 48 weeks for ll prior-prtil nd nullresponder ptients 28 weeks for undetetle HCV RNA t weeks 8 nd 24 for tretmentnïve ptients 36 weeks for undetetle HCV RNA t weeks 8 nd 24 for priorrelpse nd prtilresponder ptients 48 weeks for detetle HCV RNA t week 8 nd undetetle t week 24 for tretment-nïve, prior-relpse nd prtilresponder ptients $49,200 for 12 weeks telprevir $17,175 for 24 weeks PR $34,349 for 48 weeks PR $26,410 for 24 weeks oeprevir $35,213 for 32 weeks oeprevir $20,037 for 28 weeks PR $25,762 for 36 weeks PR $34,349 for 48 weeks PR Sme s ove 48 weeks $48,418 for 44 weeks oeprevir $34,349 for 48 weeks PR Soure: Produt lels with presriing informtion for telprevir 11 nd oeprevir. 10 Tretment durtion for telprevir depends on response. Cost estimtes sed on wholesle quisition ost (WAC) prie in Septemer PR regimen ssumed peginterferon lf-2 nd rivirin dosed t 1,200 mg dily. FDA = U.S. Food nd Drug Administrtion; HCV = heptitis C virus; IU = interntionl unit; mg = milligrm; ml = milliliter; PR = peginterferon + rivirin; RNA = rionulei id; SVR = sustined virologi response. ommon in the United Sttes. 3 For every 100 people infeted with HCV, people will develop hroni infetion; will develop hroni liver disese; 5-20 will develop irrhosis; nd 1-5 will die of irrhosis or liver ner. 7 Aute HCV illness mnifests symptomtilly in 20%-30% of ptients. 4 Possile symptoms inlude dominl pin, fever, ftigue, loss of ppetite, nuse, nd vomiting. The remining 70%-80% of ptients my e symptomti or experiene only mild symptoms. 4 The Amerin Assoition for the Study of Liver Diseses (AASLD) Prtie Guidelines (2011) represent the gold stndrd for guidne on the mngement of heptitis C. 6 These guidelines were pproved nd re supported y the AASLD, the Infetious Diseses Soiety of Ameri, nd the Amerin College of Gstroenterology. 6 The omintion of pegylted interferon (peginterferon) nd rivirin hs een the stndrd reommended tretment for HCV prior to the relese of the protese inhiitors. 6 Telprevir nd oeprevir were pproved y the U.S. Food nd Drug Administrtion (FDA) in My 2011 in omintion with peginterferon lf nd rivirin for the tretment of genotype 1 hroni heptitis C in dult ptients with ompensted liver disese, inluding irrhosis, who re tretment-nïve or who hve een previously treted with interferon-sed tretment (Tle 1). 8,9 Both gents inhiit the NS3/4A serine protese essentil for replition of HCV. 10,11 The introdution of the protese inhiitors, or diretly ting ntivirls, signifintly hnges the lndspe of HCV mngement for oth tretmentnïve nd tretment-experiened ptients. 686 Journl of Mnged Cre Phrmy JMCP Novemer/Deemer 2011 Vol. 17, No. 9
3 FIGURE 1 Key word telprevir for pulition through Septemer 15, rtiles identified 50 rtiles exluded for not eing in English or out humns 131 rtiles exluded for not eing phse 3 linil trils or RCTs Flowhrt of Literture Seletion Limits: English, humn, linil tril, or rndomized ontrolled tril Key word oeprevir for pulition through Septemer 15, rtiles identified 43 rtiles exluded for not eing in English or out humns 79 rtiles exluded for not eing phse 3 linil trils or RCTs 3 rtiles for review 2 rtiles for review Drug Telprevir (Inivek) 11 TABLE 2 Boeprevir (Vitrelis) 10 Lel Wrnings Serious skin retions (drug rsh with eosinophili nd systemi symptoms, Stevens-Johnson Syndrome), rsh, nemi Anemi, neutropeni Sfety Wrnings for Telprevir nd Boeprevir Other Adverse Retions Hemorrhoids, noretl disomfort, nl pruritus, dysgeusi, ftigue, pruritus, nuse, dirrhe Ftigue, nuse, hedhe, dysgeusi Contrindited Meditions Speifi to Telprevir or Boeprevir torvsttin rmzepine, phenoritl, phenytoin, drosperinone Contrindited Meditions for Both Telprevir nd Boeprevir lfuzosin, rifmpin, dihydroergotmine, ergonovine, ergotmine, methylergonovine, ispride, St. John s Wort, lovsttin, simvsttin, pimozide, sildenfil, tdlfil, trizolm, orl midzolm RCT = rndomized ontrolled tril. The purpose of this rtile is to () provide n overview of the linil dt for telprevir nd oeprevir, inluding the phrmokinetis, phse 3 pivotl tril effiy, nd sfety; nd () offer insight to mnged re deision mkers on mngement strtegies for HCV sed on ftors tht inlude linil dt, ost, need for dherene, nd overge determintion. Serh Method nd Results A MEDLINE review ws performed for rtiles pulished nd ville through Septemer 15, 2011, using keywords telprevir nd oeprevir with n emphsis on pulished rndomized ontrolled trils (Figure 1). The literture serh ws limited to rtiles in English, linil trils, rndomized ontrolled trils, nd reserh onduted in humns; review rtiles nd met-nlyses were exluded. Additionl informtion ws otined from the FDA wesite. Phrmokinetis Telprevir. Telprevir is ioville nd sored in the smll intestine. 12 For optiml exposure, telprevir must e tken with food (not low ft). Systemi exposure (re under the urve [AUC]) is inresed y 237% in onjuntion with stndrd ft mel (533 kilolories nd 21 grms ft) ompred with the fsted stte. When o-dministered with peginterferon, mximum onentrtion t stedy stte (C mx,ss ) nd AUC re inresed y 43% nd 38%, respetively. Rivirin does not ffet telprevir plsm onentrtions, nd mximum plsm onentrtions re rehed in 4 to 5 hours fter dose. 13 In vitro studies hve shown telprevir to e sustrte nd inhiitor of P-glyoprotein (P-gp) nd CYP3A, resulting in linilly signifint drug intertions (see Tle 2). 13 Telprevir is 59% to 76% ound to plsm proteins (lph-1-id glyoprotein nd lumin). In the phse 2 studies PROVE 2 nd PROVE 3, popultion phrmokineti nlysis ws performed using phrmokineti dt from ll sujets. After orl dministrtion, the pprent totl lerne ws out 31.6 liters (L) per hour nd 37.5 L per hour in PROVE 2 nd PROVE 3, respetively. 13 Telprevir undergoes hepti metolism, nd primry route of elimintion is fel. Elimintion hlf-life is 4 to 4.7 hours. Boeprevir. Boeprevir should e tken with food, ut type of mel nd timing re not ruil. Clinil trils demonstrted oeprevir AUC inresed up to 65% when tken with food. 14 Boeprevir rehes mximum plsm onentrtion 3 hours fter dose. An in vitro study showed oeprevir to e P-gp sustrte. 14,10 Boeprevir is lso CYP3A4/5 sustrte nd strong inhiitor nd is pproximtely 75% plsm protein ound (see Tle 2 for linilly signifint drug intertions). 14 In vitro studies showed oeprevir to e primrily metolized through the ldoketoredutse (AKR)-medited pthwy to ketone-redued metolites (intive). Men pprent lerne of oeprevir is 157 L per hour, nd its elimintion hlflife is pproximtely 3.4 hours. The primry route of elimintion is fel. Effiy nd Sfety Telprevir. The effiy nd sfety of telprevir ws studied in three phse 3 pivotl trils: ADVANCE (Telprevir for Previously Untreted Chroni Heptitis C Virus Infetion), 15 ILLUMINATE (Response-Guided Telprevir Comintion Tretment for Heptitis C Virus Infetion), 16 nd REALIZE (Telprevir for Retretment of HCV Infetion). 17 The study designs, smples, nd effiy nd sfety outomes re shown in Tle 3. Vol. 17, No. 9 Novemer/Deemer 2011 JMCP Journl of Mnged Cre Phrmy 687
4 TABLE 3 Effiy nd Sfety Results from Phse 3 Trils of Telprevir Study/Drug Regimens Design/Smple Results ADVANCE 15 T12PR: Triple therpy (telprevir with peginterferon lf-2 plus rivirin [PR]) for 12 weeks After the first 12 weeks, ptients with extended RVR d reeived 12 dditionl weeks of PR lone (totl tretment durtion 24 weeks) Ptients lking extended RVR d reeived 36 dditionl weeks of PR lone (totl tretment durtion 48 weeks) T8PR: Triple therpy for 8 weeks followed y pleo plus PR for 4 weeks After the first 12 weeks, ptients with extended RVR d reeived 12 dditionl weeks of PR lone (totl tretment durtion 24 weeks) Ptients lking extended RVR d reeived 36 dditionl weeks of PR lone (totl tretment durtion 48 weeks) PR: Pleo plus PR for 12 weeks followed y PR lone for n dditionl 36 weeks (totl tretment durtion 48 weeks) The following doses were used: telprevir 750 mg orlly every 8 hours with food peginterferon lf mg suutneously weekly rivirin 1,000 mg orlly dily (ptients weighing < 75 kg) or rivirin 1,200 mg orlly dily (ptients weighing 75 kg) Therpy ws stopped if HCV RNA levels were > 1,000 IU per ml t week 4 (T12PR nd T8PR groups; only telprevir disontinued); < 2 log 10 derese from seline in HCV RNA levels ourred t week 12 (disontinue ll drugs); or hd detetle HCV RNA t ny time etween weeks 24 nd 40 (disontinue ll drugs). ILLUMINATE 16 T12PR24: Triple therpy (telprevir plus PR) for 12 weeks, followed y PR lone for 12 weeks (totl tretment durtion 24 weeks) T12PR48: Triple therpy for 12 weeks, followed y PR lone for 36 weeks (totl tretment durtion = 48 weeks) The following doses were used: telprevir 750 mg orlly with food every 8 hours peginterferon lf mg suutneously weekly rivirin 1,000 mg orlly dily (ptients weighing < 75 kg) or rivirin 1,200 mg orlly dily (ptients weighing 75 kg) Therpy ws stopped if HCV RNA levels were > 1,000 IU per ml t week 4 (only telprevir disontinued); < 2 log 10 derese in HCV RNA from seline ourred t week 12; or hd detetle HCV RNA etween weeks 24 nd 36. Phse 3, doule-lind, pleoontrolled RCT Inlusion Criteri 18 to 70 yers of ge HCV genotype 1 infetion with evidene of hroni heptitis, s onfirmed y mens of liver iopsy within 1 yer efore sreening for the study (inluding ptients with ompensted liver irrhosis) Seronegtivity for heptitis B surfe ntigen nd the sene of ntiodies ginst humn immunodefiieny virus types 1 nd 2 Asolute neutrophil ounts t lest 1,500 per mm 3 Pltelet ounts t lest 90,000 per mm 3 Hemogloin levels t lest 12 gm per dl for women or t lest 13 gm per dl for men Exlusion Criteri Deompensted liver disese Liver disese from other uses Heptoellulr rinom Bseline Chrteristis Well lned etween tretment groups 58% mle, 9% lk,11% Hispni 21% ridging firosis or irrhosis 59% HCV sutype 1 40% HCV sutype 1 1% HCV sutype unknown Averge HCV RNA (log 10 IU per ml): 6.3 in ll groups 77% with HCV RNA 800,000 IU per ml Phse 3, open-lel, rndomized, noninferiority tril. Results of HCV RNA testing were doule-linded through week 24. Inlusion Criteri Age etween 18 nd 70 yers Presene of hroni infetion with HCV genotype 1, indited y dignosis t more thn 6 months efore the sreening visit, with detetle HCV RNA level t the visit, s well s no previous tretment for HCV infetion Seronegtive test for heptitis B virus nd humn immunodefiieny virus Asolute neutrophil ount of 1,500 or more per mm 3 Pltelet ount of 90,000 or more per mm 3 Hemogloin level of 12 gm or more per dl for femle ptients or 13 gm or more per dl for mle ptients Liver iopsy within 1 yer efore sreening visit or underwent the proedure during the sreening period unless iopsy more thn 1 yer previously showed evidene of irrhosis Exlusion Criteri Hepti deompenstion Clinilly signifint liver disese from nother use Ative ner within the previous 5 yers (exept treted sl-ell rinom) Bseline Chrteristis Well lned etween tretment groups 60% mle, 14% lk, 10% Hispni or Ltino 16% ridging firosis 72% HCV sutype 1 27% HCV sutype 1 1% HCV sutype unknown 79% with HCV RNA 800,000 IU per ml Tretment Group T12PR T8PR PR P Vlue Versus PR n = 363 n = 364 n = 361 Effiy outomes, % (n) SVR t 24 weeks 75 (271) 69 (250) 44 (158) < Undetetle HCV RNA t 72 weeks 73 (265) 67 (243) 44 (158) RVR 68 (246) 66 (242) 9 (34) Extended RVR d 58 (212) 57 (207) 8 (29) Relpse e 6 (17) 7 (18) 27 (51) Sfety outomes, % (n) Rsh f 37 (133) 35 (129) 24 (88) DC due to rsh 7 (24) 5 (17) 1 (2) Anemi g 37 (135) 39 (141) 19 (70) DC due to AEs 10 (36) 10 (37) 7 (26) Sustined virologi response. Undetetle (lower limit of detetion 10 IU per ml) plsm HCV RNA 24 weeks fter the lst plnned study dose of ptient s ssigned tretment. Primry endpoint. Lower limit of detetion 10 IU per ml. Rpid virologi response, defined s undetetle HCV RNA t week 4. d Undetetle HCV RNA t weeks 4 nd 12. e Undetetle HCV RNA levels t the end of the tretment period, ut onfirmed detetle HCV RNA levels some time etween the end of tretment nd 24 weeks fter lst study dose. f Rsh ws ezemtous nd reversed y disontinuing telprevir. Stevens-Johnson syndrome ourred in 1 ptient out 11 weeks fter ompleting telprevir tretment. g Hemogloin level <10 gm per dl: ESAs were not used to mnge nemi; the rivirin dose ws redued in ordne with produt leling (the effiy of the regimen is not ompromised if rivirin is redued; rivirin onentrtions hieved re similr to tht of full dosing in nonnemi ptient). DC = disontinution. Rndomly Assigned to T12PR24 Rndomly Assigned to T12PR48 Tretment Group n = 162 n = 160 Effiy outomes, % (n) SVR t 24 weeks 92 (149) 88 (140) RVR 100 (162) 99 (159) Extended RVR 100 (162) 99 (159) Relpse d 6 (9) 3 (4) Sfety outomes, % (n) Rsh 37 (60) 39 (62) DC due to rsh 9 (14) 6 (10) Anemi e 42 (68) 41 (66) DC due to AEs 13 (21) 12 (20) Sustined virologi response. Undetetle (lower limit of detetion pproximtely 10 to 15 IU per ml) plsm HCV RNA level t end of tretment phse nd 24 weeks fter the lst plnned study dose. Primry endpoint. Overll, 72% (n = 540) of enrolled ptients hieved SVR. Undetetle HCV RNA level t week 4. Undetetle HCV RNA level t week 4 nd week 12. d Undetetle HCV RNA t end of tretment, ut detetle fter the end of tretment. e Determined y investigtors opinion. ESAs were not used to mnge nemi; the rivirin dose ws redued in ordne with produt leling (the effiy of the regimen is not ompromised if rivirin is redued; rivirin onentrtions hieved re similr to tht of full dosing in nonnemi ptient). DC = disontinution. 688 Journl of Mnged Cre Phrmy JMCP Novemer/Deemer 2011 Vol. 17, No. 9
5 TABLE 3 Effiy nd Sfety Results from Phse 3 Trils of Telprevir (ontinued) Study/Drug Regimens Design/Smple Results REALIZE 17 T12PR48: Triple therpy (telprevir plus PR) for 12 weeks, followed y pleo plus PR for 4 weeks, nd then PR lone for 32 weeks (totl tretment durtion 48 weeks) Led-in T12PR48: Pleo plus PR for 4 weeks, followed y triple therpy for 12 weeks nd then PR lone for 32 weeks (totl tretment durtion = 48 weeks) PR48 (ontrol): Pleo plus PR for 16 weeks, followed y PR for 32 weeks (totl tretment durtion = 48 weeks) The following doses were used: telprevir 750 mg orlly every 8 hours peginterferon lf mg suutneously weekly rivirin 1,000 mg orlly dily or 1,200 mg orlly dily (weight sed) Ptients were strtified y seline virl lod (HCV RNA < 800,000 or 800,000 IU per ml) nd type of previous response to peginterferon-rivirin (no response, prtil response, or relpse). Therpy ws stopped if HCV RNA levels were > 100 IU per ml t weeks 4, 6, nd 8 fter strt of telprevir tretment (T12PR48 nd led-in T12PR48 groups; only telprevir disontinued); < 2 log 10 derese from seline in HCV RNA levels ourred t week 12 (T12PR48 group nd ontrol groups) or week 16 (led-in T12PR48 group); or hd detetle HCV RNA t week 24 or 36. Phse 3 doule lind, pleo-ontrolled RCT Inlusion Criteri 18 to 70 yers of ge Chroni HCV genotype 1 infetion Did not hve SVR to 1 previous ourse of PR despite reeiving t lest 80% of the intended dose Detetle HCV RNA Liver iopsy within 18 months efore sreening Asolute neutrophil ount 1,200 per mm 3 Pltelet ount 90,000 per mm 3 Hemogloin levels t lest 12 gm per dl for women or t lest 13 gm per dl for men Exlusion Criteri Deompensted liver disese Liver disese from other uses Heptoellulr rinom Bseline Chrteristis Well lned etween tretment groups 70% mle, 5% lk, 11% Hispni 26% irrhosis 53% previous relpse 19% prtil response 28% no response 45% HCV sutype 1 45% HCV sutype 1 HCV sutype unknown (1 ptient) Averge seline HCV RNA (log 10 IU per ml): 6.6 in ll groups 88.5% with HCV RNA 800,000 IU per ml Tretment Group Led-in T12PR48 T12PR48 PR48 n = 266 n = 264 n = 132 P Vlue Versus PR48 SVR t 24 weeks, % (n) Previous relpse 83 (121/145) 88 (124/141) 24 (16/68) < No response or prtil 41 (50/121) 41 (51/123) 9 (6/64) < response to previous therpy Previous prtil response 59 (29/49) 54 (26/48) 15 (4/27) < No previous response d 29 (21/72) 33 (25/75) 5 (2/37) < All ptients < Relpse, % (n) Previous relpse 7 (10/135) 7 (9/138) 65 (30/46) Lk previous virologi response Previous prtil response 21 (8/39) 25 (9/36) 0 No previous response 27 (8/30) 25 (9/36) 60 (3/5) Sfety outomes: ll ptients, % (n) Rsh 37 (99) 36 (95) 19 (25) DC due to rsh 5 (12) 4 (10) 0 Anemi e 30 (79) 36 (94) 15 (20) DC due to AEs 15 (39) 11 (29) 3 (4) SVR is the primry endpoint defined s undetetle (lower limit of detetion 10 IU per ml) HCV RNA 24 weeks fter lst plnned study dose. Undetetle HCV RNA t the end of previous ourse of therpy with HCV RNA positivity therefter. 2 log 10 derese in HCV RNA fter 12 weeks of therpy ut with detetle HCV RNA. d < 2 log 10 derese in HCV RNA fter 12 weeks of therpy. e Determined y investigtors opinion. ESAs were not used to mnge nemi; the rivirin dose ws redued in ordne with produt leling (the effiy of the regimen is not ompromised if rivirin is redued; rivirin onentrtions hieved re similr to tht of full dosing in nonnemi ptient). DC = disontinution. AE = dverse event; dl = deiliter; ESA = erythropoiesis-stimulting gent; gm = grm; HCV = heptitis C virus; kg = kilogrm; IU = interntionl units; mg = mirogrm; mm 3 = ui millimeters; PR = peginterferon+rivirin; RCT = rndomized ontrolled tril; RNA = rionulei id; RVR = rpid virologi response; SVR = sustined virologi response. Boeprevir. The effiy nd sfety of oeprevir ws studied in two phse 3 pivotl trils: SPRINT-2 (Boeprevir for Untreted Chroni HCV Genotype 1 Infetion) nd RESPOND-2 (Boeprevir for Previously Treted Chroni HCV Genotype 1 Infetion). The study designs, smples, nd effiy nd sfety outomes re shown in Tle 4. Mnged Cre Considertions The rrivl of the protese inhiitors hs hd signifint impt on the mngement of genotype 1 heptitis C. Both gents hve demonstrted signifintly improved sustined virologi response (SVR) rtes ompred with onventionl dul therpy with peginterferon nd rivirin. However, oth protese inhiitors introdue issues tht mnged re deision mkers will need to ddress in order to optimize ost-effetive use. Deision mkers need to onsider inresed totl drug tretment osts, ptient mngement nd dherene, omprtive sfety nd effiy, nd pproprite utiliztion mngement ontrols when deiding on strtegy for heptitis C tretment. Hed-to-hed omprtive linil trils re lking etween telprevir nd oeprevir. Both gents hve studies in tretment-nïve nd previous prtil responders, ut only telprevir hs een studied in prior null responders. 17 AASLD guidelines reommend the use of telprevir for prior null responders. 6 Although oth gents were studied with peginterferon, telprevir ws used with peginterferon lf-2 while oeprevir trils used peginterferon lf-2. There my e speultion tht the overll effiy of the protese inhiitors ould e ffeted y hoie of peginterferon euse there re effiy differenes etween peginterferon lf-2 nd lf-2 in the heptitis C popultion. Some pyers my require the use of one speifi peginterferon in utiliztion mngement progrm, regrdless of the protese inhiitor used. Current literture nd FDA leling for the protese inhiitors does not support the use of one distint peginterferon produt over the other. The rtionle for peginterferon preferred produt seletion y pyer ould e multifeted, inluding produt ost, mnufturer disounts, hnnel steerge, nd linil differenes. In ross-tril omprisons, telprevir ppers to hve Vol. 17, No. 9 Novemer/Deemer 2011 JMCP Journl of Mnged Cre Phrmy 689
6 TABLE 4 Effiy nd Sfety Results from Phse 3 Trils of Boeprevir Study/Drug Regimens Design/Smple Results SPRINT-2 18 Phse 3 pleo-ontrolled RCT Control: PR for 4 weeks (led-in period), followed y pleo plus PR for 44 weeks (totl tretment durtion 48 weeks) Response-guided: PR for 4 weeks (led-in period), followed y oeprevir plus PR for 24 weeks Ptients would end therpy if HCV levels were undetetle (lower limit of detetion 9.3 IU per ml) from week 8 through 24 (totl tretment durtion 28 weeks) Otherwise, ptients reeived pleo plus PR for n dditionl 20 weeks (totl tretment durtion 48 weeks) Fixed durtion: PR for 4 weeks (led-in period), followed y oeprevir plus PR for 44 weeks (totl tretment durtion = 48 weeks) The following doses were used: oeprevir 800 mg orlly 3 times dily with food peginterferon lf mg per kg suutneously weekly rivirin weight-sed dosing 600 to 1,400 mg orlly dily in divided doses in morning nd evening Ptients were enrolled seprtely into 2 ohorts: lks nd nonlks, due to differenes in SVR etween the groups. They were strtified y genotype 1 sutype ( or ) nd HCV RNA level ( 400,000 IU per ml or > 400,000 IU per ml). Ptients disontinued tretment if they hd detetle HCV RNA level t week 24. Inlusion Criteri 18 yers of ge or older Chroni infetion with HCV genotype 1 with no previous history of HCV tretment Plsm HCV RNA level 10,000 IU per ml Weight 40 to 125 kg Exlusion Criteri Liver disese not relted to heptitis C Deompensted irrhosis Renl insuffiieny HIV or heptitis B infetion Pregnny or urrent restfeeding Ative ner Bseline Chrteristis Well lned etween tretment groups 60% mle, 14% lk, 82% white, 4% other 64% HCV sutype 1 33% HCV sutype 1 3% HCV sutype unknown 85% with HCV RNA > 800,000 IU per ml Tretment Group Response- Fixed Control Guided Durtion n = 363 n = 368 n = 366 P Vlue Versus Control SVR t 24 weeks, % (n) All ptients 38 (137) 63 (233) 66 (242) < Nonlk ohort 40 (125/311) 67 (211/316) 68 (213/311) < Blk ohort 23 (12/52) 42 (22/52) 53 (29/55) 0.040; Relpse, % (n) All ptients 22 (39/176) 9 (24/257) 9 (24/265) < Sfety outomes: ll ptients, % (n) Anemi 29 (107) 49 (182) 49 (179) < ESA use 24 (87) 43 (159) 43 (159) < Men durtion of ESA in dys DC due to nemi 1.1(4) 1.6 (6) 1.9 (7) Neutrophil ount 500 to 14 (50) 24 (87) 25 (90) < < 750 per mm 3 (grde 3) Dysguesi 18 (64) 37 (137) 43 (156) < DC due to AEs 16 (57) 12 (45) 16 (60) SVR is the primry endpoint defined s undetetle (lower limit of detetion 9.3 IU per ml) HCV RNA levels for 24 weeks fter ompleting therpy. Detetle HCV RNA levels during follow-up despite undetetle levels t the end of tretment. Hemogloin < 10 gm per dl. Rivirin dose ws redued or ESA dministered t the disretion of investigtors (the effiy of the regimen is not ompromised if rivirin is redued; rivirin onentrtions hieved re similr to tht of full dosing in nonnemi ptient). DC = disontinution. RESPOND-2 19 Control: PR for 4 weeks (led-in period), followed y pleo with PR for 44 weeks (totl tretment durtion 48 weeks) Response-guided: PR for 4 weeks (led-in period), followed y oeprevir with PR for 32 weeks Ptients would end therpy if HCV RNA levels were undetetle (lower limit of detetion 9.3 IU per ml) t week 8 nd 12 (totl tretment durtion 36 weeks) Ptients with detetle level t week 8 ut undetetle t week 12 reeived PR for n dditionl 12 weeks (totl tretment durtion 48 weeks) Fixed durtion: PR for 4 weeks (led-in period), followed y oeprevir with PR for 44 weeks (totl tretment durtion = 48 weeks) The following doses were used: oeprevir 800 mg orlly 3 times dily with food peginterferon lf mg per kg suutneously weekly rivirin weight-sed dosing 600 to 1,400 mg orlly dily in divided doses t morning nd evening Ptients were strtified y previous response to therpy (nonresponse or relpse) nd HCV sutype (1 or 1). Nonresponse ws defined s derese in the HCV RNA level t lest 2 log 10 IU per ml y week 12 ut with detetle level during therpy period. Relpse ws defined s undetetle (lower limit of detetion 9.3 IU per ml) HCV RNA level t the end of tretment, ut detetle levels during follow-up. Ptients disontinued ll tretment if they hd detetle HCV RNA level t week 12. Phse 3 pleo-ontrolled RCT Inlusion Criteri 18 yers of ge or older Chroni infetion with HCV genotype 1 nd prior response to interferon (minimum 12-week durtion of therpy) Plsm HCV level 10,000 IU per ml Weight 40 to 125 kg Exlusion Criteri Heptitis B or infetion with humn immunodefiieny virus Liver disese not relted to heptitis C Deompensted liver disese Unontrolled dietes mellitus Severe psyhitri disorder Ative sustne use Bseline Chrteristis 67% mle, 12% lk, 86% white, 2% other 47% HCV sutype 1 44% HCV sutype 1 9% HCV sutype unknown 12% irrhosis 88% with HCV RNA > 800,000 IU per ml Tretment Group Response- Fixed Control Guided Durtion n = 80 n = 162 n = 161 P Vlue Versus Control Effiy outomes, % (n) SVR t 24 weeks 21 (17) 59 (95) 66 (107) < Erly response 9 (7) 46 (74) 52 (84) SVR mong erly responders 100 (7/7) 86 (64/74) 88 (74/84) Relpse 31 (25) 15 (17) 12 (14) Sfety outomes, % (n) Anemi d 20 (16) 43 (70) 46 (74) < ESA use e 21 (17) 41 (66) 46 (74) 0.003; < DC due to nemi (5) Neutrophil ount 500 to 9 (7) 19 (30) 20 (32) 0.060; < 750 per mm 3 (grde 3) Dysgeusi 11 (9) 43 (69) 45 (72) < DC due to AEs 2 (2) 8 (13) 12 (20) 0.150; Primry endpoint defined s undetetle (lower limit of detetion 9.3 IU per ml) HCV RNA levels t week 24 fter ompleting therpy. Undetetle HCV RNA level t week 8. Undetetle HCV RNA level t the end of tretment, ut detetle levels during follow-up. d Hemogloin level <10 gm per dl. Rivirin dose ws redued or n ESA dministered t the disretion of investigtors. Effiy of the regimen is not ompromised if rivirin is redued; rivirin onentrtions hieved re similr to tht of full dosing in nonnemi ptient. e A totl of 16 ptients who reeived ESA lso reeived red lood-ell trnsfusion. DC = disontinution. AE = dverse event; dl = deiliter; ESA = erythropoiesis-stimulting gent; gm = grm; HCV = heptitis C virus; HIV = humn immunodefiieny virus; kg = kilogrm; IU = interntionl units; mg = mirogrm; ml = milliliter; PR = peginterferon + rivirin; RCT = rndomized ontrolled tril; RNA = rionulei id; RVR = rpid virologi response; SVR = sustined virologi response. 690 Journl of Mnged Cre Phrmy JMCP Novemer/Deemer 2011 Vol. 17, No. 9
7 signifintly elevted risk of rsh ompred with oeprevir (22% vs. 2% in previously untreted ptients). 10,11 Stevens- Johnson syndrome ourred in 1 ptient out 11 weeks fter ompleting telprevir tretment. 15 Anemi ppered to our t similr rtes with telprevir nd oeprevir in ross-tril omprisons (19% vs. 20% in previously untreted ptients). 10,11 Although nemi ws mnged differently in the linil trils (telprevir ptients reeived rivirin dose/frequeny modifitions, nd oeprevir ptients reeived erythropoiesis-stimulting gents [ESAs]), prtitioners will likely onsider the use of ESAs with either protese inhiitor depending on their own linil experiene with these gents. 15,17-19 Mnged re pyers my inlude provisions in utiliztion mngement progrms tht mnge nemi in ptients reeiving either of the protese inhiitors with rivirin dose redution (effiy of the regimen is not ompromised if the rivirin dose is redued; rivirin onentrtions hieved will e similr to tht of full dosing in nonnemi ptient) nd llow the use of ESAs t prtiulr hemogloin levels if rivirin dose redution is insuffiient to mnge nemi. Comprtive trils nd studies in different ptient sugroups, inluding those with humn immunodefiieny virus (HIV) oinfetion, re needed to fully understnd the differenes etween the protese inhiitors. Drug Cost Telprevir nd oeprevir will ring sustntil new phrmy osts to the mngement of heptitis C. The wholesle quisition ost (WAC) of telprevir is $97.62 per 375 milligrm (mg) tlet nd $13.10 per 200 mg tlet of oeprevir. 20 Full tretment osts will vry onsiderly depending on tretment durtion, drug hoie, nd ptient mix. Bsed on WAC priing, the ost of 12 weeks of telprevir would e $49,200.48, nd oeprevir WAC would rnge from $26, for 24 weeks to $48, for 44 weeks of therpy, in ddition to the osts for peginterferon plus rivirin (Tle 1). Telprevir s higher ost my e lned y the signifintly esier dosing regimen of telprevir (12 weeks in ll ses) versus the more onfusing, response-guided oeprevir regimen. Additionl osts will e inurred in the mngement of dverse effets from the orl gents. Anemi mnged y ESAs would dd signifint ost to the regimen versus mngement vi rivirin dose redution. Rtes of nemi were 36% in the telprevir-treted ptients versus 17% for ptients treted only with peginterferon nd rivirin. 11 Anemi ourred in 45%-50% of oeprevir-treted ptients versus 20%-30% of ptients treted only with peginterferon nd rivirin. 10 In the SPRINT-2 tril, nemi with oeprevir ws mnged vi ESA 40,000 units dministered weekly, with men durtion of 94 weeks of ESA therpy in the response-guided group nd 156 weeks in the fixed-durtion group versus 121 weeks in the peginterferon-rivirin group. 18 Forty-three perent of oeprevir-treted ptients reeived ESAs ompred with 24% of ptients reeiving only peginterferon plus rivirin in linil trils. 10 The WAC of vil of 40,000 units of ESA is $ Depending on the durtion of therpy, ESAs ould dd signifintly to the totl osts of the regimens of the protese inhiitors. Lortory monitoring nd lini visits my lso e inresed s ptients re monitored for response nd dherene. Prior to the pprovl of the protese inhiitors, MAdm- Mrx et l. (2011) found tht verge totl ll-use osts were $19,665 per ptient per yer (PPPY) in 2009 dollrs for HCVinfeted ptients. 21 The ost of HCV mngement will more thn doule or triple for ptients with genotype 1 infetion treted with triple therpy. Additionlly, WAC priing does not ount for mrk-ups in phrmy provider hnnels or drug mnufturer retes. Due to the inresed osts, pyers should strongly onsider implementtion of utiliztion nd re mngement progrms tht help ensure tht the right ptients reeive the pproprite therpy nd re dherent to therpy. Utiliztion Mngement A linilly foused, omprehensive utiliztion mngement progrm is impertive in the mngement of heptitis C. The utiliztion mngement riteri should inlude the following ftors: pproprite ptient seletion, onomitnt therpy, sfety onsidertions, dosing, nd ontinution of therpy. Approprite ptient seletion my exlude groups not studied in phse 3 trils with the orl protese inhiitors, inluding virl genotypes other thn 1 nd individuls with HIV oinfetion. In these groups, tretment with the stndrd dul therpy my e pplile. Conomitnt therpy with peginterferon nd rivirin is ritil to the suess of protese inhiitor therpy. Utiliztion mngement progrms my e used to mndte triple therpy in ptients with genotype 1 infetion unless they hve ontrinditions to the protese inhiitors. A utiliztion mngement progrm should lso ensure pproprite dosing of protese inhiitors nd peginterferon s well s pprovl of therpy durtions limited to wht is neessry to omplete tretment. Both telprevir nd oeprevir hve numerous ontrinditions nd serious drug intertions. Coverge riteri should onsider sreening for these situtions prior to pproving therpy. Finlly, oth protese inhiitors hve guidelines regrding tretment futility (Figure 2). These riteri predit tretment filures sed on virl lods t speifi time points. Mngement progrms my inlude these stopping points vertim to ensure ptients re eing monitored nd responding to therpy. However, if mnged re deision mkers deide to follow the futility rules, 2 points must e onsidered. First, overge pprovls should extend eyond required lortory heks to llow for reporting of virl lods without the ptient running out of medition. Seond, meeting the futility rules should stop overge of oth the protese inhiitor nd the peginterferon. Vol. 17, No. 9 Novemer/Deemer 2011 JMCP Journl of Mnged Cre Phrmy 691
8 FIGURE 2 Heptitis C Tretment Algorithm: Telprevir nd Boeprevir Telprevir Futility Rules Week 4 HCV RNA level 1,000 IU per ml DISCONTINUE ALL THERAPY Week 12 HCV RNA level 1,000 IU per ml DISCONTINUE ALL THERAPY Week 24 HCV RNA level 10 IU per ml DISCONTINUE ALL THERAPY Week 1 Triple therpy: telprevir + PR PR Disontinue telprevir Continution Rules Tretment-nȉve* nd prior-relpse ptients: Week 24 Week 48 Not detetle t week 4 nd week 12 ontinue PR through week 24 *for ptients with irrhosis ontinue PR through week 48 unless detetle t week 24 Detetle t week 4 nd/or week 12 ontinue PR through week 48 unless detetle t week 24 Prior prtil- nd null-responder ptients: Week 48 Not detetle t week 4 nd week 12 ontinue PR through week 48 unless detetle t week 24 Boeprevir Futility Rules Week 1 Week 8 HCV RNA level (Undetetle: 9.3 IU per ml) Week 4 Begin oeprevir Week 12 HCV RNA level 100 IU per ml DISCONTINUE ALL THERAPY Week 28 HCV RNA level 9.3 IU per ml DISCONTINUE ALL THERAPY PR Triple therpy: oeprevir + PR Continution Rules Tretment-nȉve ptients: Week 28 Not detetle t week 8 nd week 24 ontinue triple therpy with oeprevir + PR through week 28 Week 48 Detetle t week 8 nd not detetle t week 12 omplete oeprevir t week 36 nd ontinue PR through week 48 Prior-relpse nd prtil-responder ptients: Week 36 Not detetle t week 4 nd week 24 ontinue triple therpy with oeprevir + PR through week 36 Week 48 Detetle t week 8 nd not detetle t week 12 omplete oeprevir t week 36 nd ontinue PR through week 48 Ptients with irrhosis: Week 48 4 weeks of PR followed y 44 weeks of triple therpy with oeprevir + PR Soure: Telprevir (Inivek) presriing informtion. 11 Soure: Boeprevir (Vitrelis) presriing informtion. 10 HCV = heptitis C virus; IU = interntionl units; ml = milliliter; PR = peginterferon + rivirin; RNA = rionulei id. 692 Journl of Mnged Cre Phrmy JMCP Novemer/Deemer 2011 Vol. 17, No. 9
9 Ptient dherene is ruil to the ost-effetive use of the protese inhiitors in heptitis C. Nondherent ptients re t signifint risk of tretment filure nd resistne development. 22 Mnged re deision mkers my implement re mngement progrm in onjuntion with utiliztion mngement riteri to ensure ptients re monitored for pproprite use nd dherene to therpy. Mny speilty phrmies hve experiene in re mngement of heptitis C. Idelly, re mngement progrm would inlude regulr (weekly or monthly) lls from phrmist to the ptient to ssess urrent dherene to therpy. Presription lims ould lso e monitored to ensure onsistent filling, nd ll ould e pled to memers suspeted of hving gp in re. Pyers my onsider limiting distriution of heptitis C tretments to speilty phrmy tht offers omprehensive re mngement to ptients. Finlly, mnged re deision mkers should edute the speilty phrmy nd prtitioners on the speifis of the utiliztion mngement riteri, whih will redue potentilly duplitive efforts y the pyer nd the speilty phrmy in re requirements, suh s lortory tests, or potentilly inonsistent periods for pproved durtion of therpy. Provider edution ould e delivered vi trining modules nd/or hving sujet mtter expert ville to nswer questions on the riteri. The relese of telprevir nd oeprevir mrks unique event in whih 2 disese-hnging therpies reeived FDA pprovl within dys of eh other. Suh events provide pyers with the opportunity to gther informtion nd dt on how new therpies re dopted, lter existing utiliztion of estlished therpies, nd impt medil nd phrmy osts. Prime Therpeutis reported tht the utiliztion of drugs for heptitis C deresed y 22.1% in 2010 ompred with 2009, ontriuting to 15.2% derese in drug ost for these drugs (-$0.03 per memer per month), 9% of whih ws in medil enefit osts nd 91% ws in phrmy enefit osts. 23 Although phrmy osts will inrese with the use of the protese inhiitors, the totl ost of ring for ptients with heptiti C infetion should derese due to the inresed ure rtes with the protese inhiitors. The relese of the protese inhiitors will use the first surge in use of heptitis C gents s tretment-nïve nd previously treted ptients ttempt therpy. Pyers should gther dt on the hnges in utiliztion nd how the different produts perform (e.g., use of presription lims to determine utiliztion trend, ost per lim fter pplile disounts, nd medil lims informtion to monitor for dverse events suh s nemi). This informtion ould prove useful in determining the vlue tht the mrket ples on different spets of ompeting drugs inluding dosing, sfety profile, ost, nd effetiveness of utiliztion mngement tools. Additionlly, omprehensive dt olletion ould further define the true ost of the 2 gents when tking into onsidertion disounts, hnnel, nd dverse events. Conlusions With FDA pprovl of the new protese inhiitors, deision mkers hve mny ftors to onsider in developing strtegy round heptitis C. Inresed drug osts, ptient mngement, dherene, omprtive sfety nd effiy, nd pproprite utiliztion mngement ontrols re importnt issues. Despite the gret dvnement in heptitis C tretment, the protese inhiitors hve signifint dverse effet profile nd pill urden. An pproprite utiliztion mngement strtegy should e implemented to ensure ptients reeive optiml enefit from therpy. Authors Alexndr Tungol, PhrmD, is Phrmy Resident; Kellie Rdemher, PhrmD, is Senior Clinil Phrmist; nd Jeremy A. Shfer, PhrmD, MBA, is Senior Diretor of Utiliztion Mngement, Prime Therpeutis LLC, Egn, Minnesot. AUTHOR CORRESPONDENCE: Jeremy A. Shfer, PhrmD, MBA, Prime Therpeutis LLC, 1305 Corporte Center Dr., Egn, MN Tel.: ; Fx: ; E-mil: jshfer@primetherpeutis.om. DISCLOSURES There ws no externl funding for this mnusript. The uthors re employees of Prime Therpeutis LLC, phrmy enefits mngement ompny whose ownership inludes helth plns. Conept nd design were performed y Tungol nd Shfer. Dt olletion nd interprettion were performed primrily y Tungol with the ssistne of Rdemher nd Shfer. The mnusript ws written primrily y Tungol nd Shfer nd revised primrily y Tungol nd Rdemher. REFERENCES 1. Colvin HM, Mithell AE, eds. Committee on the Prevention nd Control of Virl Heptitis Infetions. Heptitis nd Liver Cner: A Ntionl Strtegy for Prevention nd Control of Heptitis B nd C. Wshington, DC: Institute of Mediine, The Ntionl Ademies Press; Aville t: np.edu/tlog.php?reord_id= Aessed Otoer Europen Assoition for the Study of the Liver. EASL Clinil Prtie Guidelines: mngement of heptitis C virus infetion. Journl of Heptology. 2011;55(2): Aville t: files/47d873f9f_file.pdf. Aessed Otoer 28, U.S. Centers for Disese Control. Heptitis C informtion for helth professionls. Mrh 14, Aville t: index.htm. Aessed Otoer 28, Ferguson M. Current therpies for hroni heptitis C. Phrmotherpy. 2011;31(1): Wong JB, MQuilln GM, MHuthison JG, Poynrd T. Estimting future heptitis C moridity, mortlity, nd osts in the United Sttes. Am J Puli Helth. 2000;90(10): Aville t: pm/rtiles/pmc /?tool=pumed. Aessed Otoer 28, Vol. 17, No. 9 Novemer/Deemer 2011 JMCP Journl of Mnged Cre Phrmy 693
10 6. Ghny MG, Nelson DR, Strder DB, Thoms DL, Seeff LB. An updte on tretment of genotype 1 hroni heptitis C virus infetion: 2011 prtie guideline y the Amerin Assoition for the Study of Liver Diseses. Heptology. 2011;54(4): U.S. Centers for Disese Control. Heptitis C. June Aville t: Aessed Otoer U.S. Food nd Drug Administrtion. FDA news relese. FDA pproves Inivek for heptitis C. My 23, Aville t: NewsEvents/Newsroom/PressAnnounements/um htm. Aessed Otoer 28, U.S. Food nd Drug Administrtion. FDA news relese. FDA pproves Vitrelis for heptitis C. My 13, Aville t: NewsEvents/Newsroom/PressAnnounements/um htm. Aessed Otoer 28, Vitrelis (oeprevir) psules. Merk. My Aville t: Aessed Otoer 28, Inivek (telprevir) film oted tlets. Vertex. My Aville t: Aessed Otoer 28, Perni RB, Almquist SJ, Byrn RA, et l. Prelinil profile of VX-950, potent, seletive, nd orlly ioville inhiitor of heptitis C virus NS3-4A serine protese. Antimiro Agents Chemother. 2006;50(3): Aville t: d&id=pmid: Aessed Otoer 28, U.S. Food nd Drug Administrtion. Center for Drug Evlution nd Reserh. Clinil phrmology nd iophrmeutis review of telprevir. Applition numer July 8, Aville t: Aessed Otoer 28, U.S. Food nd Drug Administrtion. Center for Drug Evlution nd Reserh. Clinil phrmology nd iophrmeutis review of oeprevir. Applition numer June 14, Aville t: essdt.fd.gov/drugstfd_dos/nd/2011/202258orig1s000clinphr mr.pdf. Aessed Otoer 28, Joson IM, MHuthison JG, Dusheiko G, et l., for the ADVANCE Study Tem. Telprevir for previously untreted hroni heptitis C virus infetion. N Engl J Med. 2011;364(25): Aville t: nejm.org/doi/full/ /nejmo Aessed Otoer 28, Shermn KE, Flmm SL, Afdhl NH, et l., for the ILLUMINATE Study Tem. Response-guided telprevir omintion tretment for heptitis C virus infetion. N Engl J Med. 2011;365(11): Aville t: Aessed Otoer 28, Zeuzem S, Andreone P, Pol S, et l., for the REALIZE Study Tem. Telprevir for retretment of HCV infetion. N Engl J Med. 2011; 364(25): Aville t: NEJMo Aessed Otoer 28, Poordd F, MCone J Jr, Bon BR, et l., for the SPRINT-2 Investigtors. Boeprevir for untreted hroni HCV genotype 1 infetion. N Engl J Med. 2011;364(13): Aville t: NEJMo Aessed Otoer 28, Bon BR, Gordon SC, Lwitz E, et l., for the RESPOND-2 Investigtors. Boeprevir for previously treted hroni HCV genotype 1 infetion. N Engl J Med. 2011;364(13): Aville t: full/ /nejmo Aessed Otoer 28, Wolters Kluwer Helth. Medi-Spn Mster Drug Dt Bse v2.5 (MDDB). Aessed Septemer 20, MAdm-Mrx C, MGrry LJ, Hne CA, Biskupik J, Deniz B, Brixner DI. All-use nd inrementl per ptient per yer ost ssoited with hroni heptitis C virus nd ssoited liver omplitions in the United Sttes: mnged re perspetive. J Mng Cre Phrm. 2011;17(7): Aville t: spx?id= Lo Re V 3rd, Tel V, Lolio AR, Amoros VK, Kpln DE, Gross R. Reltionship etween dherene to heptitis C virus therpy nd virologi outomes: ohort study. Ann Intern Med. 2011;155(6): Prime Therpeutis Drug Trend Insights. August Aville t: pdf. Aessed Otoer 28, Journl of Mnged Cre Phrmy JMCP Novemer/Deemer 2011 Vol. 17, No. 9
Perspective Management of Advanced Fibrosis in the Context of Hepatitis C Virus Infection
Perspetive Mngement of Advned Firosis in the Context of Heptitis C Virus Infetion Advned firosis my e present in sustntil proportion of individuls with symptomti, hroni heptitis C virus (HCV) infetion,
More informationEFFECT OF DIETARY ENZYME ON PERFORMANCE OF WEANLING PIGS
EFFECT OF DIETARY ENZYME ON PERFORMANCE OF WEANLING PIGS Finl report sumitted to Dniso Animl Nutrition E. vn Heugten nd B. Frederik North Crolin Stte University, Deprtment of Animl Siene Summry The urrent
More informationP AND K IN POTATOES. Donald A Horneck Oregon State University Extension Service
P AND K IN POTATOES Donld A Hornek Oregon Stte University Extension Servie INTRODUCTION Phosphorous nd potssium re importnt to grow high yielding nd qulity pottoes. Muh of the northwest hs hd trditionlly
More informationWhangarei District Council Class 4 Gambling Venue Policy
Whngrei Distrit Counil Clss 4 Gmling Venue Poliy April 2013 Whngrei Distrit Counil Clss 4 Gmling Venue Poliy Tle of ontents Introdution... 3 1 Ojetives of the poliy in so fr s promoted y the Gmling At
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not inlude ll the informtion needed to use sfely nd effetively. See full presriing informtion for. (nivolum) injetion, for intrvenous use Initil
More informationFibromyalgia (FM) is a chronic pain condition that, by
n report n Preglin: An Alph 2 -delt ( 2 -d) Lignd for the Mngement of Firomylgi Lesley Arnold, MD; Philip Mese, MD; nd Sturt Silvermn, MD Ojetive: To review the effiy nd sfety of preglin, n lph 2 -delt
More informationThe Hepatitis C treatment landscape is changing in Pakistan
The Heptitis C tretment lndscpe is chnging in Pkistn 01 A new dwn hs emerged in ccess to HCV Cure Ferozsons is herlding the chnge in the Heptitis C lndscpe of Pkistn In prtnership with Giled Sciences,
More informationEfficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationIntroduction to Study Designs II
Introdution to Study Designs II Commonly used study designs in publi helth & epidemiologi reserh Benjmin Rihrd H. Muthmbi, DrPH, MPH Stte HIV Epidemiologist HIV Epidemiology Investigtion Setion PA Deprtment
More informationAJ PUTT. Hematology. Chemistry. Species: Canine Gender: Female Year of Birth: 2013 Client: PUTT
Speies: Cnine Gender: Femle Yer of Birth: 2013 Client: PUTT Requisition #: 9034-12 Aession #: W2152816 Aount Code: 72364 Veterinrin: CARTER Pnel/Profile: Tik Pnel Add-on Senior Profile with L 4Dx Plus
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationBE PREPARED FOR THE FLU SEASON WITH BE PREPARED FOR THE FLU SEASON WITH
BE PREPARED FOR THE 2015-2016 FLU SEASON WITH BE PREPARED FOR THE 2015-2016 FLU SEASON WITH offers the following produt enefits: E xperiened mnufturer with yer-round sesonl prodution for oth the Northern
More informationALIMTA Frequently Asked Questions
Frequently Asked Questions Here re the nswers to some frequently sked questions out. Tlk to your dotor if you need more informtion. Question: Wht is dvned nonsqumous NSCLC? Answer: There re two min types
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationAFLURIA, Influenza Vaccine Suspension for Intramuscular Injection Formula Initial U.S. Approval: 2007
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not inlude ll the informtion needed to use sfely nd effetively. See full presriing informtion for., Influenz Vine Suspension for Intrmusulr Injetion
More informationSpecific Immunotherapy in Atopic Dermatitis Four- Year Treatment in Different Age and Airborne Allergy Type Subgroups
At Dermtovenerol Crot 2006;14(4):230-240 CLINICAL ARTICLE Speifi Immunotherpy in Atopi Dermtitis Four- Yer Tretment in Different Age nd Airorne Allergy Type Sugroups Mgdlen Czrnek-Operz, Wojieh Silny Deprtment
More informationOther Uses for Cluster Sampling
Other Uses for Cluster Smpling Mesure hnges in the level of n ttriute Hypothesis testing versus intervl estimtion Type I n 2 errors Power of the test Mesuring ttriute t sme time in ifferent sites Exmple:
More informationCAUSES OF DIARRHEA, PNEUMONIA, AND ABORTION IN 1991 CATTLE SUBMISSIONS TO THE KSU VETERINARY DIAGNOSTIC LABORATORY
CAUSES OF DIARRHEA, PNEUMONIA, AND ABORTION IN 1991 CATTLE SUBMISSIONS TO THE KSU VETERINARY DIAGNOSTIC LABORATORY 1 1 2 R. K. Frnk, M. W. Vorhies, nd M. M. Chengpp Summry Cuses of dirrhe, pneumoni, nd
More informationEffects of Enzyme Inducers in Therapeutic Efficacy of Rosiglitazone: An Antidiabetic Drug in Albino Rats
Asin J. Exp. Si., Vol. 21, No. 2, 2007, 00-00 Effets of Enzyme Inuers in Therpeuti Effiy of Rosiglitzone: An Antiieti Drug in Alino Rts Ann Chursi,#* P.K. Krr** A. S. Mnn* & M.D. Khry* * Deprtment of Phrmeutil
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationEffects of flurbiprofen on renal function in patients with moderate renal insufficiency
Br. J. lin. Phrm. (1992), 33, 385-393 ffets of fluriprofen on renl funtion in ptients with moderte renl insuffiieny M. D. MURRAY12, P. K. GRN', D. C. BRATR', A. K. MANATUNGA' & S. D. HALL' 'Division of
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationEFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE
Swine Dy 22 Contents EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE B. J. Johnson, J. P. Kyser, J. D. Dunn, A. T. Wyln, S. S. Dritz 1, J.
More informationAnthony Traboulsee 1*, David K. B. Li 1, Mark Cascione 2, Juanzhi Fang 3, Fernando Dangond 4 and Aaron Miller 5
Troulsee et l. BMC Neurology (18) 18:68 https://doi.org/1.1186/s12883-18-166-8 RESEARCH ARTICLE Preditive vlue of erly mgneti resonne imging mesures is differentilly ffeted y the dose of interferon et-1
More informationNonpharmacologic Interventions for Treatment-Resistant Depression in Adults Executive Summary
Comprtive Effectiveness Review Numer 33 Effective Helth Cre Progrm Nonphrmcologic Interventions for Tretment-Resistnt Depression in Adults Executive Summry Bckground Mjor depressive disorder (MDD) is common
More informationOpen Access RESEARCH ARTICLE. Genetics Selection Evolution
DOI 10.1186/s12711-016-0222-0 Genetis Seletion Evolution RESEARCH ARTICLE Open Aess Comprison of host geneti ftors influening pig response to infetion with two North Amerin isoltes of porine reprodutive
More informationPoultry No The replacement value of betaine for DL-methionine and Choline in broiler diets
Poultry No. 1573 The replement vlue of etine for DL-methionine nd Choline in roiler diets Key Informtion In roiler diets defiient in sulfur mino ids ut dequtely supplemented with methyl groups vi dded
More informationUniversity of Groningen
University of Groningen The prevlene of sesonl ffetive disorder in the Netherlnds Mersh, PPA; Middendorp, HM; Bouhuys, Antoinette; Beersm, DGM; vn den Hoofdkker, RH; Middendorp, Hermine M. Pulished in:
More informationAnti-Tumour Necrosis Factor-alpha Therapy in Crohn s Disease: Clinical and Health Economic Aspects
Anti-Tumour Nerosis Ftor-α Therpy in Crohn s Disese Anti-Tumour Nerosis Ftor-lph Therpy in Crohn s Disese: Clinil n Helth Eonomi Aspets Fion MGuire, 5th yer Meiine ABSTRACT Ojetives: Crohn s isese is hroni,
More informationInput from external experts and manufacturer on the 2 nd draft project plan Stool DNA testing for early detection of colorectal cancer
Input externl experts nd mnufcturer on the 2 nd drft project pln Stool DNA testing for erly detection of colorectl cncer (Project ID:OTJA10) All s nd uthor s replies on the 2nd drft project pln Stool DNA
More informationTHE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS
THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY
More informationXII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV
XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies
More informationMinimum effective dose of chenic acid for gallstone patients: reduction with bedtime administration and
Gut, 1982, 23, 28-284 Minimum effetive dose of heni id for gllstone ptients: redution with bedtime dministrtion nd low holesterol diet D P MUDGL, R M KUPFER, ND T C NORTHFIELD* From the Normn Tnner Gstroenterology
More informationEffects of Feeding Citrus Pulp or Corn Supplements With Increasing Levels of Added Undegraded Intake Protein on the Performance of Growing Cattle
Effets of Feeding Citrus Pulp or Corn Supplements With Inresing Levels of Added Undegrded Intke Protein on the Performne of Growing Cttle Deke Alkire Todd Thrift Willim Kunkle 1 Citrus pulp-sed supplements
More informationProvider How To. Software Process Service Results
Softwre Proess Servie Results Provier How To Copyright Glenwoo Systems LLC 2010. The informtion herein remins the property of Glenwoo Systems LLC. This informtion my not e reprinte or uplite, n is governe
More informationInjury and Illness Casualty Distributions among U.S. Army and Marine Corps Personnel during Operation Iraqi Freedom
MILITARY MEDICINE, 173, 3:247, 2008 Injury nd Illness Csulty Distriutions mong U.S. Army nd Mrine Corps Personnel during Opertion Irqi Freedom Jmes M. Zouris, BS*; Amer L. Wde, MPH ; Cheryl P. Mgno, MPH
More informationCASE REPORT. Abstract. Introduction. Case Reports
CASE REPORT Ulertive Colitis-ssoited Cner/Dysplsi Deteted Using Surveillne Colonosopy Performed in the Clinil Remission Phse: A Report of Five Cses Ruiko Murok 1, Keiihi Toming 1, Xuin Si 1, Kzuhiro Tkenk
More informationPRODUCT INFORMATION. XIAFLEX (collagenase clostridium histolyticum) Lyophilised powder for injection 900 micrograms/vial NAME OF THE MEDICINE
PRODUCT INFORMATION (ollgense lostridium histolytium) Lyophilised powder for injetion 900 mirogrms/vil NAME OF THE MEDICINE Ative: ollgense lostridium histolytium CAS: Clostridium histolytium gene olg
More informationBright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit
Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document
More informationSUPPLEMENTARY INFORMATION
DOI: 1.138/n358 TLR2 nd MyD88 expression in murine mmmry epithelil supopultions. CD24 min plus MRU Myo-epithelil Luminl progenitor (CD61 pos ) Mture luminl (CD61 neg ) CD49f CD61 Reltive expression Krt5
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationSupplementary Figure 1. Scheme of unilateral pyramidotomy used for detecting compensatory sprouting of intact CST axons.
() BDA 2 weeks fter Py () AAVs Cre or GFP t P1 BDA 2 weeks fter Py CSMN CST () Py t P7 or 2 months () Py t 2 months Supplementry Figure 1. Sheme of unilterl pyrmidotomy used for deteting ompenstory sprouting
More informationEFFECT OF SOYBEAN CYST NEMATODE ON GROWTH OF DRY BEAN. Research Report to Northarvest Bean Growers, January 19, 2009
EFFECT OF SOYBEAN CYST NEMATODE ON GROWTH OF DRY BEAN Reserh Report to Northrvest Ben Growers, Jnury 19, 29 Berlin D. Nelson, Susilo Poromrto, n Ruell Goswmi, Dept. Plnt Pthology, NDSU Ojetive: Determine
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationBilling and Coding Guide. Hospital Outpatient Department
illing nd oding Guide Hospitl Outptient Deprtment overge, coding, nd pyment in the hospitl outptient deprtment ONPTTRO (ptisirn) received US Food nd Drug dministrtion (FD) pprovl on 10 ug 2018, nd is indicted
More informationSignal Detection of Docetaxel in Canadian Spontaneous Adverse Event Reports
Shrwn Singhl et l. / Journl of Phrmy Reserh 01,5(), Reserh Artile Avilble online through ISSN: 0974-6943 http://jprsolutions.info Signl Detetion of Doetxel in Cndin Spontneous Adverse Event Reports Shrwn
More informationThe effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice
Antivirl Therpy 215; 2:11 19 (doi: 1.3851/IMP2744) Originl rtile The effet of intrvenous permivir, ompred with orl oseltmivir, on the outome of post-influenz pneumool pneumoni in mie Akitk Tnk 1, Shigeki
More informationEffects of exercise training on hepatic steatosis in high fat diet-induced obese mice
Effets of exerise trining on hepti stetosis in high ft diet-indued oese mie Hyunsik Kng, PhD Sungkyunkwn University Non-Aloholi Ftty Liver Disese (NAFLD) A reversile ondition tht is hrterized y hepti lipid
More informationSUPPLEMENTARY INFORMATION
DOI: 1.13/n7 Reltive Pprg mrna 3 1 1 Time (weeks) Interspulr Inguinl Epididyml Reltive undne..1.5. - 5 5-51 51-1 1-7 7 - - 1 1-1 Lipid droplet size ( m ) 1-3 3 - - - 1 1-1 1-1 1-175 175-3 3-31 31-5 >5
More informationReduction in albumin binding function following liver resection in patients with and without cirrhosis
Originl Artile Redution in lumin inding funtion following liver resetion in ptients with nd without irrhosis Penglei Ge 1,2, Wenjun Lio 1, Huyu Yng 1, Jingfen Lu 3, Wei Xu 1, Dndn Hu 1, Shund Du 1, Hifeng
More informationFor citation purposes, the electronic version is the definitive version of this article:
Professionl I s s u e s Too Use Cesstion Servies Provided y Dentists nd Dentl Hygienists in Mnito: Prt 1. Influene of Prtitioner Demogrphis nd Psyhosoil Ftors Dougls J. Brothwell, BEd, DMD, MS, DDPH; Shirley
More informationSummary of Package Insert 1
Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded
More informationTNF-a Downregulates Filaggrin and Loricrin through c-jun N-terminal Kinase: Role for TNF-a Antagonists to Improve Skin Barrier
ORIGINAL ARTICLE TNF- Downregultes Filggrin nd Loririn through -Jun N-terminl Kinse: Role for TNF- Antgonists to Improve Skin Brrier Byung Eui Kim, Mihel D. Howell,, Emm Guttmn,, Ptrii M. Gilleudeu, Irm
More informationHYPERBILIRUBINEMIA BY RICARDO KATZ, HECTOR DUCCI, AND HERNAN ALESSANDRI
INFLUNC OF CORTISON AND PRDNISOLON ON HYPRBILIRUBINMIA BY RICARDO KATZ, HCTOR DUCCI, AND HRNAN ALSSANDRI (From the Deprtment of Mediine, University of Chile Medil Shool, Hospitl Slvdor, Sntigo, Chile)
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationLHb VTA. VTA-projecting RMTg-projecting overlay. Supplemental Figure 2. Retrograde labeling of LHb neurons. a. VTA-projecting LHb
SUPPLEMENTARY INFORMATION Supplementl Figure 1 doi:10.1038/nture09742 Lterl 1.0 mm from midline mpfc BNST mpfc BNST Lterl 2.1 mm from midline LHA LHA Lterl 2.7 mm from midline SUPPLEMENTAL INFORMATION
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationInvasive Pneumococcal Disease Quarterly Report July September 2018
Invsive Pneumococcl Disese Qurterly Report July Septemer Introduction Since 17 Octoer 2008, invsive pneumococcl disese (IPD) hs een notifile to the locl Medicl Officer of Helth under the Helth Act 1956.
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationAlimonti_Supplementary Figure 1. Pten +/- Pten + Pten. Pten hy. β-actin. Pten - wt hy/+ +/- wt hy/+ +/- Pten. Pten. Relative Protein level (% )
Alimonti_Supplementry Figure 1 hy 3 4 5 3 Neo 4 5 5 Proe 5 Proe hy/ hy/ /- - 3 6 Neo β-tin d Reltive Protein level (% ) 15 1 5 hy/ /- Reltive Gene Expr. (% ) 15 1 5 hy/ /- Supplementry Figure 1 Chrteriztion
More informationSUPPLEMENTARY INFORMATION
{ OI: 1.138/n31 Srifie n nlyze APs on week 1 s of iet 1 4 6 High-ft iet BrU High-ft iet BrU 4 High-ft iet BrU 6 High-ft iet BrU Lin - Lin - : C34 + : C9 + 1 1 3 1 4 1 5 C45 1 C34 1 1 1 1 3 1 4 1 5 S-1
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationThe Disappearance of Lymph Node Metastasis from Neuroendocrine Carcinoma after Endoscopic Ultrasound-guided Fine Needle Aspiration
CASE REPORT The Dispperne of Lymph Node Metstsis from Neuroendorine Crinom fter Endosopi Ultrsound-guided Fine Needle Aspirtion Msyuki Shit 1, Hiroyuki Mtsuyshi 1, Akiko Todk 2, Hnko Kuri 3, Noyuki Tsutsumi
More informationAntiviral Therapy 2015; 20: (doi: /IMP2825)
Antivirl Therpy 2015; 20:209 216 (doi: 10.3851/IMP2825) Originl rticle Cost-effectiveness of boceprevir co-dministrtion versus pegylted interferon-2b nd ribvirin only for ptients with heptitis C genotype
More informationSUPPLEMENTARY INFORMATION
doi: 1.138/nture862 humn hr. 21q MRPL39 murine Chr.16 Mrpl39 Dyrk1A Runx1 murine Chr. 17 ZNF295 Ets2 Znf295 murine Chr. 1 COL18A1 -/- lot: nti-dscr1 IgG hevy hin DSCR1 DSCR1 expression reltive to hevy
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationARTICLE. E. O. List & A. J. Palmer & D. E. Berryman & B. Bower & B. Kelder & J. J. Kopchick
Dietologi (2009) 52:1647 1655 DOI 10.1007/s00125-009-1402-z ARTICLE Growth hormone improves ody omposition, fsting lood gluose, gluose tolerne nd liver triylglyerol in mouse model of diet-indued oesity
More informationLipid Composition of Egg Yolk and Serum in Laying Hens Fed Diets Containing Black Cumin (Nigella sativa)
Interntionl Journl of Poultry Siene 5 (6): 574-578, 2006 ISSN 682-8356 Asin Network for Sientifi Informtion, 2006 Lipid Composition of Egg Yolk nd Serum in Lying Hens Fed Diets Contining Blk Cumin (Nigell
More informationAntithrombotic Therapy in Peripheral Artery Disease : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American
Antithromboti Therpy in Peripherl Artery Disese : Antithromboti Therpy nd Prevention of Thrombosis, 9th ed: Amerin College of Chest Physiins Clinil Prtie Guidelines Evidene-Bsed Pblo Alonso-Coello, Sergi
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescriing informtion for ALIMTA. ALIMTA (pemetrexed for injection)
More informationPRACTICE GUIDELINE SERIES
PRACTICE GUIDELINE SERIES 131 I Tositumom in lymphom M.C. Cheung MD,* J.A. McEchern MD,* A.E. Hynes,* R.M. Meyer MD,* K. Imrie md* nd the Memers of the Hemtology Disese Site Group # of Cncer Cre Ontrio
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationGlycemic Index: The Analytical Perspective
FEATURE Glyemi Index: The Anlytil Perspetive Jon W. DeVries Generl Mills, In. Minnepolis, MN The purpose of siene, nd thus, the role of the sientist, is generlly elieved to e to pursue the disovery, development,
More informationDiabesity & Associated Disorders in Australia
Diesity & Associted Disorders in Austrli - 2000 The Accelerting Epidemic The Austrlin Dietes, Oesity nd Lifestyle Study (AusDi) Authors Dr D Dunstn, Professor P Zimmet, Professor T Welorn, Dr R Sicree,
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 01/2018 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. (rifximin) tlets, for orl use Initil U.S.
More informationVariations in burn perfusion over time as measured by portable ICG fluorescence: A case series
Burns & Trum, Otoer 2014, Vol 2, Issue 4 Cse Report Vritions in urn perfusion over time s mesured y portle ICG fluoresene: A se series Shrmil Dissnike, Senn Adul-Hmed, John A. Griswold Deprtment of Surgery,
More information308 nm excimer lamp in combination with topical tacrolimus: A retrospective study of its efficacy and safety in childhood vitiligo
ORIGINAL ARTICLE 308 nm excimer lmp in comintion with topicl tcrolimus: A retrospective study of its efficcy nd sfety in childhood vitiligo BS Chndrshekr, N Shoh, P Deprtment of Dermtology, Cutis, Acdemy
More informationRESEARCH ARTICLE. Supplemental Figure 5
11.5 2 2 11. RESEARCH ARTICLE RBC ( 1 12 /L) 1.5 1. 9.5 PLT ( 1 9 /L) 1 16 14 HGB (g/l) 19 1 17 16 9. 12 4 4 46 Cellulr & Moleulr Immunology dvne online pulition, PCV (%) 44 MCV (fl) 46 44 ; doi:1.13/mi.214.16
More information(% of adherent cells) *** PBL firm adhesion. Frequency (% ) 4 1 L 2 CXCR3 DP-2
Chemotxis (% of dded ells) PBL totl dhesion (N ells/mm 2 /1.1 6 PBL) Frequeny (% ) PBL firm dhesion Supplementry Figure 1 4 4 3 3 2 2 1.1-4 1-3 1.1.2. 1 1 8 6 4 2 Adiponetin ( g/ml) - + Adiponetin ( g/ml)
More informationOptimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality
Optimistion of diets for Atlntic cod (Gdus morhu) roodstock: effect of rchidonic cid on egg & lrvl qulity Dr Gordon Bell, Ms. An Blnco, Dr Bill Roy, Dr Derek Roertson, Dr Jim Henderson nd Mr Richrd Prickett,
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationInfluence of Ad libitum or Control Feeding on the Performance of Broilers Fed Diets Low in Crude Protein 1
Interntionl Journl of Poultry Siene 4 (5): 74-79, 005 ISSN 168-8356 Asin Network for Sientifi Informtion, 005 Influene of Ad liitum or Control Feeding on the Performne of Broilers Fed Diets Low in Crude
More informationEffect of supplemental fat from dried distillers grains with solubles or corn oil on cow performance, IGF-1, GH, and NEFA concentrations 1
Effect of supplementl ft from dried distillers grins with solules or corn oil on cow performnce, IGF-1, GH, nd NEFA concentrtions 1 Aigil Brtosh 2, Cody Wright 3, Aimee Wertz-Lutz 4, nd George Perry 5
More informationSUPPLEMENTARY INFORMATION
DOI: 1.138/n2977 Numer of ells per field 6 4 2 P =.1 Orthotopi eum Normlized ventrl photon flux 1E7 1E6 1E5 1E4 1E3 1E2 n=8 n=9 1 2 3 4 5 6 Dys Dy54 1.5E5 2.4E7 d Mie with lymph node metstsis (%) 1 8 6
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationTOURNAMENT REGULATIONS INDOOR COMPETITIONS
TOURNAMENT REGULATIONS INDOOR COMPETITIONS Jnury 2015 INTERNATIONAL HOCKEY FEDERATION CONTENTS 1 Rules of ompetition 2 Tournment Offiils 3 Tem entry 4 Pre-tournment riefing meetings 5 Composition of tem
More informationMEDALIST Trial Background and Rationale
The MEDALIST Tril: Results of Phse 3, Rndomized, Double-Blind, Plcebo-Controlled Study of to Tret Ptients With Very Low-, Low-, or Intermedite-Risk Myelodysplstic Syndromes (MDS) Associted Anemi With Ring
More informationTOURNAMENT REGULATIONS INDOOR COMPETITIONS
TOURNAMENT REGULATIONS INDOOR COMPETITIONS Novemer 2017 INTERNATIONAL HOCKEY FEDERATION CONTENTS 1 Rules of ompetition 2 Tournment offiils 3 Tem entry 4 Pre-tournment riefing meetings 5 Composition of
More informationOptimizing Metam Sodium Fumigation in Fine-Textured Soils
Optimizing Metm Sodium Fumigtion in Fine-Textured Soils Neil C Gudmestd University Distinguished Professor & Endowed Chir of Potto Pthology Deprtment of Plnt Pthology North Dkot Stte University Erly Dying
More informationScientific investigations
Sientifi investigtions Depression nd Sleep-Relted Symptoms in n Adult, Indigenous, North Amerin Popultion Colleen L. Froese, M.D. 1,2 ; Arsln Butt, M.S. 2,3 ; Aln Mulgrew, M.D. 2,3 ; Rupi Cheem, R.N. 2
More informationORIGINAL INVESTIGATION. Predictive Relationship Between Depression and Physical Functioning After Coronary Surgery
ORIGINAL INVESTIGATION Preditive Reltionship Between Depression nd Physil Funtioning After Coronry Surgery Friederike Kendel, PhD; Götz Gelbrih, PhD; Mrkus Wirtz, PhD; Elke Lehmkuhl, MD; Nin Knoll, PhD;
More informationManagement of Relapsed/Refractory Follicular Lymphoma
April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn
More informationResearch Article A Comparison of Inflammatory and Oxidative Stress Markers in Adipose Tissue from Weight-Matched Obese Male and Female Mice
Hindwi Pulishing Corportion Experimentl Dietes Reserh Volume 1, Artile ID 859395, 8 pges doi:1.1155/1/859395 Reserh Artile A Comprison of Inflmmtory nd Oxidtive Stress Mrkers in Adipose Tissue from Weight-Mthed
More informationCombined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice
http://www.kidney-interntionl.org & 26 Interntionl Soiety of Nephrology originl rtile Comined AGE inhiition nd ACEi dereses the progression of estlished dieti nephropthy in B6 d/d mie F Zheng 1,2, Y-j
More informationAntiviral Therapy 2015; 20: (doi: /IMP2920)
Antivirl Therpy 2015; 20:397 405 (doi: 10.3851/IMP2920) Originl rticle Sfety, tolerbility nd phrmcokinetics of dorvirine, novel HIV non-nucleoside reverse trnscriptse inhibitor, fter single nd multiple
More informationProduct Monograph. Published by
Product Monogrph Pulished y INDICATION AND LIMITATION OF USE JARDIANCE is indicted s n djunct to diet nd exercise to improve glycemic control in dults with type 2 dietes mellitus. JARDIANCE is not recommended
More information